Physician profile
Steven E Miller
NPI 1669477287
$2,207.34
in general payments reported to CMS, 2019-2025
15 companies · $40.25 in 2025
The $40.25 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $384 · 2021: $675 · 2022: $452 · 2023: $23.38 · 2024: $34.07 · 2025: $40.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $899.81 | 2019-2022 | |
| Amgen INC. | $379.74 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $220.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $186.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.92 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $83.31 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $70.13 | 2019 | |
| Merck Sharp & Dohme LLC | $58.04 | 2021-2023 | Bridion |
| Janssen Pharmaceuticals, INC | $49.91 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $45.67 | 2019-2021 | |
| Amarin Pharma, INC. | $25.51 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $25.38 | 2019 | |
| Sumitomo Pharma America, INC. | $24.71 | 2025 | Gemtesa |
| Lexicon Pharmaceuticals, INC. | $17.40 | 2024 | |
| Boston Scientific Corporation | $15.54 | 2025 | Enroute Transcarotid Neuroprotection System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.